<?xml version="1.0" encoding="UTF-8"?>
<ref id="B57-pharmaceuticals-12-00101">
 <label>57.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Bullard-Feibelman</surname>
    <given-names>K.M.</given-names>
   </name>
   <name>
    <surname>Govero</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Zhu</surname>
    <given-names>Z.</given-names>
   </name>
   <name>
    <surname>Salazar</surname>
    <given-names>V.</given-names>
   </name>
   <name>
    <surname>Veselinovic</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Diamond</surname>
    <given-names>M.S.</given-names>
   </name>
   <name>
    <surname>Geiss</surname>
    <given-names>B.J.</given-names>
   </name>
  </person-group>
  <article-title>The FDA-approved drug sofosbuvir inhibits Zika virus infection</article-title>
  <source>Antivir. Res.</source>
  <year>2017</year>
  <volume>137</volume>
  <fpage>134</fpage>
  <lpage>140</lpage>
  <pub-id pub-id-type="doi">10.1016/j.antiviral.2016.11.023</pub-id>
  <pub-id pub-id-type="pmid">27902933</pub-id>
 </element-citation>
</ref>
